Posts Tagged: clinical trials

Triphase announces proteasome inhibitor marizomib demonstrates potent synergistic anti-multiple myeloma activity in combination with pomalidomide

Findings from Preclinical Study Presented at American Society of Hematology 2014 Annual Meeting TORONTO AND SAN DIEGO (Dec. 6, 2014) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase II proof-of-concept clinical studies, today announced preclinical study results demonstrating that the combination of its highly differentiated proteasome inhibitor, marizomib, and pomalidomide (Pomalyst®) was synergistic in killing multiple myeloma cells. MaRS Innovation is an early-stage investor in Triphase. See our web archive for more details. Combined doses of ... Read more

AvidBiologics and National Research Council of Canada to collaborate on antibody-drug conjugates

Toronto-based AvidBiologics Inc., a leading Canadian biotech company, and the National Research Council of Canada (NRC) are collaborating on one of the most promising advances in the fight against cancer: antibody-drug conjugates (ADCs). Recently signed research and licensing agreements will enable both organizations to continue developing a series of ADCs targeting breast, lung, and head-and-neck cancers. Unlike chemotherapy, ADCs specifically seek and destroy cancer cells, with minimal impact on healthy cells. "The work performed by NRC is crucial to assembling the data package ... Read more

MaRS Innovation joins new financing round for AvidBiologics Inc.

TORONTO, Sept. 29, 2014 — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC). Led by Lumira Capital, the financing round included MaRS Innovation (MI), MaRS Investment Accelerator Fund (IAF), Rosseau Asset Management, and the company's founding investors. This announcement was covered by Dow Jones: Private Equity and Venture Capital and by Canadian Private Equity. Today's financing builds on prior ... Read more

WaveCheck campaign part of new study on crowdfunding medical research

MI's Fazila Seker also interviewed in National Post article on what prompts medical researchers to consider crowdfunding The WaveCheck crowdfunding campaign, which raised $53,390 on Indiegogo to support clinical trials for a clinical technique invented by researchers at Sunnybrook Health Sciences Centre and Ryerson University, was included in a new Canadian-led study on the merits of crowdfunding to support cancer and rare diseases. "Crowdfunding drug development: The state of play in oncology and rare diseases," was published in Drug Discovery Today's June issue. MaRS ... Read more

WaveCheck breast cancer technology receives $100,000

OICR's catalyst grant enables WaveCheck to open first partner site at MD Anderson Cancer Center in May TORONTO, April 8, 2014 -- People with breast cancer are a step closer to knowing if their tumour is responding to chemotherapy at the start of treatment, thanks to a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR). The funding builds upon MaRS Innovation's Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over $50,000 from over 500 supporters worldwide in two months last ... Read more

Triphase signs collaboration and option agreement with Celgene Corporation, leading innovator of cancer therapies

MI portfolio company actively seeking additional products for licensing and development TORONTO and SAN DIEGO, Jan. 9, 2014 — A unique collaboration of life science leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, have formed Triphase Accelerator Corporation, an oncology development accelerator. Triphase Accelerator's announcement was covered in Yonge Street Media, Bloomburg Businessweek and Global University Venturing. Formed in 2010, Triphase Accelerator Corporation is a cancer-focused biotechnology development company that aims to reduce the ... Read more

CAMH, Assurex Health Partner to Bring Personalized Care to More Canadians

The Centre for Addiction and Mental Health and Assurex Health combine resources to bring personalized medicine in psychiatry, reducing the current trial-and-error approach TORONTO – The Centre for Addiction and Mental Health (CAMH), Canada’s leading hospital for mental health, and Assurex Health, a global leader in personalized medicine, have signed an agreement for a joint venture to bring the benefits of this treatment approach to more Canadians. The personalized approach helps to match the right medication at the right dose for each patient, based ... Read more

Bedside Paediatric Early Warning System (BedsidePEWS™) Earns FDA 510(k) Approval

Bedside Clinical Systems to bring paediatric care solution to U.S. hospitals TORONTO, Canada (October 24, 2013) — Bedside Clinical Systems (BCS)’s flagship solution, Bedside Paediatric Early Warning System (BedsidePEWSTM), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). For the complete BedsidePEWS™ FDA Medical Device listing (K124038), click here. This story was covered in Biotechnology Focus. BedsidePEWSTM tracks a patient’s vital signs, such as heart rate and blood pressure, as part of routine clinical assessments and outputs a single score to ... Read more

WaveCheck to Transform Chemotherapy Monitoring for Women with Breast Cancer

Indiegogo campaign to raise funds for North American clinical study during Breast Cancer Awareness Month; 12 artists donate 13 original works worth over $15,000 to support campaign Toronto, Canada (October 9, 2013) — WaveCheck — a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation — is poised to transform chemotherapy response monitoring for women with breast cancer. WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer ... Read more

Dr. Raphael Hofstein’s MRI blog post: How Team Ontario’s biotechnology takes on the world

Dr. Raphael (Rafi) Hofstein is president and CEO of MaRS Innovation (MI) – the commercialization agent for an exceptional research discovery pipeline stemming from 16 leading Ontario academic institutions. As a single entry point to annual member research and development activity of $1B, MI provides a gateway for investors and licensees who wish to access Ontario’s technology assets. During the 2012 BIO convention in Boston, Dr. Hofstein blogged about how CQDM of Montreal and MaRS Innovation of Toronto had teamed up to ... Read more
Page 2 of 3123